On April 13, 2026, Hisicor and US company AbbVie signed a licensing agreement for Nav1.8 inhibitors, with royalties up to $745 million.

2026.1.12 Haisco Technology’s innovative drug HSK39004 has received a global license from AirNexis, with a total amount exceeding $1 billion.

Be vigilant against "black mouth" in the stock market, stay away from illegal stock recommendations — 2025 Illegal Securities and Futures Prevention Month

The leaders of the Tibet Autonomous Region's region visited listed companies

The Political Bureau of the CPC Central Committee held a meeting to analyze and study the current economic situation and economic work. Xi Jinping, General Secretary of the CPC Central Committee, presided over the meeting.

The State Council Information Office held a press conference to introduce information on financial support for high-quality economic development

Haisco provides the “Financial Consumer Rights Protection Education Campaign Month” activity

Hisicor Pharmaceutical Group ranks among the “2024 China Innovative Pharmaceutical Companies” list

The top 100 have strength, advancing into a new phase— Warm congratulations on Haisco Pharmaceutical Group being ranked in the “2023 Chinese pharmaceutical company TOP100 list”.